Info

34. Stocchi, F.: Int. J. Clin. Pract. 60:215-221, 2006.

35. Olanow, C. W., Watts, R. L., and Koller, W. C.: Neurology 56:S1-S88, 2001.

36. Clarke, C. E., and Guttman, M.: Lancet 360:1767-1769, 2002.

37. Kvernmo, T., Härtter, S., and Burger, E.: Clin. Ther. 28:1065-1078, 2006.

38. Waller, E. A., Kaplan, J., and Heckman, M. G.: Mayo Clin. Proc. 80:1016-1020, 2005.

39. Hagan, J. J., et al.: Trends Pharmacol. Sci. 18:156-163, 1997.

40. Tan, E. K., and Jankovic, J.: Clin. Neuropharmacol. 24:247-253, 2001.

41. Jähnichen, S., Horowski, R., and Pertz, H. H.: Eur. J. Pharmacol. 513:225-228, 2005.

42. Nakatsuka, A., Nagai, M., Yabe, H., et al.: J. Pharmacol. Sci. 100:59-64, 2006.

43. Joyce, J. N., and Millan, M. J.: Curr. Opin. Pharmacol. 7:100-105, 2007.

44. Dooley, M., and Markham, A.: Drugs Aging 12:495-514, 1998.

45. Deleu, D., Northway, M. G., and Hanssens, Y.: Clin. Pharmacokinet. 41:261-309, 2002.

46. Kaye, C. M., and Nicholls, B.: Clin. Pharmacokinet. 39:243-254, 2000.

47. Matheson, A. J., and Spencer, C. M.: Drugs 60:115-137, 2000.

48. Reynolds, N. A., Wellington, K., and Easthope, S. E.: CNS Drugs 19:973-981, 2005.

49. Kreiss, D. S., Bergstrom, D. A., Gonzalez, A. M., et al.: Eur. J. Pharmacol. 277:209-214, 1995.

50. Keating, G. M., and Lyseng-Williamson, K. A.: CNS Drugs 19:165-184, 2005.

51. Gordin, A., Kaakkola, S., and Teräväinen, H.: J. Neural Transm. 111:1343-1363, 2004.

52. Jorga, K., et al.: Br. J. Clin. Pharmacol. 49:39-48, 2000.

53. LeWitt, P. A.: Pharmacotherapy 20:26S-32S, 2000.

54. Allers, K. A., et al.: Exp. Neurol. 191:104-118, 2005.

55. Matsubayashi, H., Swanson, K. L., and Albuquerque, E. X.: J. Pharmacol. Exp. Ther. 281:834-844, 1997.

56. Baldessarini, R. J., and Tarazi, F. I.: Pharmacotherapy of Psychosis and Mania. In Brunton, L. L., Parker, K., and Lazo, J. S. (eds.). Goodman & Gilman's The Pharmacological Basis of Therapeutics, 11th ed. New York, McGraw-Hill, 2006, pp. 429-460.

57. Lewis, D. A., and Lieberman, J. A.: Neuron 28:325-334, 2000.

58. McDonald, C., and Murphy, K. C.: Psychiatr. Clin. North. Am. 26:41-63, 2003.

59. Lewis, D. A., and Levitt, P.: Annual Rev. Neurosci. 25:409-432, 2002.

62. Abi-Dargham, A.: Int. Rev. Neurobiol. 78:133-164, 2007.

63. Seeman, P., and Lee, T.: Science 188:1217-1219, 1975.

65. Abi-Dargham, A., and Laruelle, M.: Eur. Psychiatry 20:15-27, 2005.

66. Davis, K. L., et al.: Am. J. Psychiatry 148:1474-1486, 1991.

67. Lieberman, J. A., Sheitman, B. B., and Kinon, B. J.: Neuropsychopharmacology 17:205-229, 1997.

68. Okubo, Y., Suhara, T., Suzuki, K., et al: Nature 385:634-636, 1997.

69. Frankle, W. G., Lerma, J., and Laruelle, M.: Neuron 39:205-216, 2003.

70. Weinberger, D. R., and Laruelle, M.: Neurochemical and Neuropharmacological Imaging in Schizophrenia. In Davis, K. L., et al. (eds.). Neuropsychopharmacology: Fifth Generation of Progress. Philadelphia, Lippincott, Williams and Wilkins, 2002, pp. 833-855.

71. Stone, J. M., Morrison, P., and Pilowsky, L. S.: J. Psychopharmacol. 21:440-452, 2007.

72. Miyamoto, S., et al.: Therapeutics of Schizophrenia. Neuropsychopharmacology: The Fifth Generation of Progress; Davis, K. L., et al., (eds.). Philadelphia, Lippincott, Williams and Wilkins, 2002, pp. 775-808.

73. Lehmann, H. E., and Ban, T. A.: Can. J. Psychiatry 42:152-162, 1997.

74. Petersen, P. V., et al.: Arzneimittelforschung 8:395-397, 1958.

75. Petersen, P. V., Lassen, N. O., and Holm, T. O.: 2-Chloro-9-(3-dimethylaminopropylidene) thiaxanthene and its amine exchange reactions; (Kefalas A/S). United States, 1964; US 3149103, 6 pp.

77. Froimowitz, M., and Cody, V.: J. Med. Chem. 36:2219-2227, 1993.

78. Feinberg, A. P., and Snyder, S. H.: Proc. Natl. Acad. Sci. U. S. A. 72:1899-1903, 1975.

79. Kaiser, C., Pavloff, A. M. Garvey, E., et al.: J. Med. Chem. 15:665-673, 1972.

80. Horn, A. S., and Snyder, S. H.: Proc. Natl. Acad. Sci. U. S. A. 68:2325-2328, 1971.

81. Grol, C. J., et al.: J. Med. Chem. 25:5-9, 1982.

82. Kaiser, C., Tedeschi, D. H., Fowler, P. J., et al.: J. Med. Chem. 14:179-186, 1971.

83. Gareri, P., et al.: Clin. Drug Investig. 23:287-322, 2003.

84. Belal, F., Hefnawy, M. M., and Aly, F. A.: J. Pharm. Biomed. Anal. 16:369-376, 1997.

85. Shen, W. W.: Biol. Psychiatry 41:814-826, 1997.

86. Fang, J., and Gorrod, J. W.: Cell. Mol. Neurobiol. 19:491-510, 1999.

87. Chetty, M., et al.: Eur. Neuropsychopharmacol. 6:85-91, 1996.

88. Terry, A. V., Gearhart, D. A., Mahadik, S. P., et al.: Neuroscience 136:519-529, 2005.

89. Wishart, D. S., Knox, C., Guo, A. C., et al.: Nucleic Acids Res. 34:D668-D672, 2006.

90. IPCS Intox Databank, 2007, http://www.intox.org/databank/ index.htm.

91. Mula, M., and Monaco, F.: Clin. Neuropharmacol. 25:280-289, 2002.

92. Janssen, P. A. J.: Haloperidol and related Butyrophenones. In Gordon, M. (ed.). Psychopharmacological Agents. Philadelphia, Academic Press, 1967, pp. 199-248.

93. Sikazwe, D. M. N., Li, S., Mardenborough, L., et al.: Bioorg. Med. Chem. Lett. 14:5739-5742, 2004.

94. Ravina, E., and Masaguer, C. F.: Curr. Med. Chem. 1:43-62, 2001.

95. Fang, J., McKay, G., Song, J., et al.: Drug Metab. Dispos. 29:1638-1643, 2001.

96. Beresford, R., and Ward, A.: Drugs 33:31-49, 1987.

97. Forsman, A., et al.: Curr. Ther. Res. 21:606-617, 1977.

98. Glue, P., and Banfield, C.: Human Psychopharmacol. 11:97-114, 1996.

99. Desta, Z., Kerbusch, T., Soukhova, N., et al.: J. Pharmacol. Exp. Ther. 285:428-437, 1998.

100. Matsui-Sakata, A., Ohtani, H., and Sawada, Y.: Drug Metab. Pharmacokinet. 20:368-378, 2005.

101. Kapur, S., and Seeman, P.: Am. J. Psychiatry 158:360-369, 2001.

102. Weiner, D. M., Burstein, E. S., Nash, N., et al.: J. Pharmacol. Exp. Ther. 299:268-276, 2001.

103. Roth, B. L., Sheffler, D., and Potkin, S. G.: Clin. Neurosci. Res. 3:108-117, 2003.

104. Dean, B., and Scarr, E.: Curr. Drug Targets CNS Neurol. Disord. 3: 217-225, 2004.

105. Horacek, J., Bubenikova-Valesova, V., Kopecek, M., et al.: CNS Drugs 20:389-409, 2006.

106. Kiss, B., and Bitter, I.: Structural Analogues of Clozapine. Analogue-Based Drug Discovery, 1st ed. In Fisher, J., and Ganellin, CR. (eds.). Research Triangle Park, Wiley-VCH, 2006, pp. 297-314.

107. Raggi, M. A., et al.: Curr. Med. Chem. 11:279-296, 2004.

108. Meltzer, H. Y.: Psychopharmacology 99:S18-S27, 1989. Psychopharmacology (Berl) 163:1-3, 2002.

109. Fang, J., et al.: Naunyn Schmiedebergs Arch. Pharmacol. 358:592-599, 1998.

110. Burstein, E. S., Ma, J., Wong, S., et al.: J. Pharmacol. Exp. Ther. 315:1278-1287, 2005.

111. Williams, D. P., et al.: J. Pharmacol. Exp. Ther. 283:1375-1382, 1997.

112. Kassahun, K., Mattiuz, E., Nyhart, E., Jr., et al.: Drug Metab. Dispos. 25:81-93, 1997.

113. Kassahun, K., et al.: Drug Metab. Dispos. 26:848-855, 1998.

114. Bymaster, F. P., and Felder, C. C.: Mol. Psychiatry 7:S57-S63, 2002.

115. Lambert, M. T., et al.: Prog. Neuropsychopharmacol. Biol. Psychiatry 30:919-923, 2006.

116. Moisan, J., et al.: Pharmacoepidemiol. Drug Saf. 14:427-436, 2005.

117. DeVane, C. L., and Nemeroff, C. B.: Clin. Pharmacokinet. 40:509-522, 2001.

118. Grimm, S. W., et al.: Br. J. Clin. Pharmacol. 61:58-69, 2006.

119. Nemeroff, C. B., Kinkead, B., and Goldstein, J.: J. Clin. Psychiatry 63:5-11, 2002.

120. Newman-Tancredi, et al.: Eur. J. Pharmacol. 428:177-184, 2001.

121. Berecz, R., Dorado, P., De La Rubia, A., et al.: Curr. Drug Targets 5:573-579, 2004.

122. Mahatthanatrakul, W., Dorado, P., De La Rubia, A., et al.: J. Clin. Pharm. Ther. 32:161-167, 2007.

123. Fang, J., Bourin, M., and Baker, G. B.: Naunyn Schmiedebergs Arch. Pharmacol. 359:147-151, 1999.

124. Yasui-Furukori, N., Hidestrand, M., Spina, E., et al.: Drug Metab. Dispos. 29:1263-1268, 2001.

125. Bork, J. A., et al.: J. Clin. Psychiatry 60:469-476, 1999.

126. Nyberg, S., et al.: Am. J. Psychiatry 156:869-875, 1999.

127. Garver, D. L.: Curr. Drug Targets 7:1205-1215, 2006.

128. Harrison, T. S., and Perry, C. M.: Drugs 64:1715-1736, 2004.

129. Winans, E.: Am. J. Health Syst. Pharm. 60:2437-2445, 2003.

130. Jordan, S., Koprivica, V., Chen, R., et al.: Eur. J. Pharmacol. 441:137-140, 2002.

131. Wood, M. D., Scott, C., Clarke, K., et al.: Eur. J. Pharmacol. 546:88-94, 2006.

132. Potkin, S. G., Saha, A. R., Kujawa, M. J., et al.: Arch. Gen. Psychiatry 60:681-690, 2003.

133. Obach, R. S., and Walsky, R. L.: J. Clin. Psychopharmacol. 25:605-608, 2005.

134. Beedham, C., Miceli, J. J., and Obach, R. S.: J. Clin. Psychopharmacol. 23:229-232, 2003.

135. Stimmel, G. L., Gutierrez, M. A., and Lee, V.: Clin. Ther. 24:21-37, 2002.

136. Beal, M. F.: J. Bioenerg. Biomembr. 36:381-386, 2004.

137. Shults, C. W., Haas, R. H., and Beal, M. F.: Biofactors 9:267-272, 1999.

138. Bonuccelli, U., and Del Dotto, P.: Neurology 67(7 Suppl 2):S30-S38, 2006.

139. Djaldetti, R., and Melamed, E.: J. Neurol. 249 Suppl 2:II30-II35, 2002.

141. Gash, D. M., Zhang, Z., Ovadia, A., et al.: Nature 380:252-255, 1996.

142. Kristiansen, L. V., Huerta, I., Beneyto, M., et al.: NMDA receptors and schizophrenia. Curr. Opin. Pharmacol. 7:48-55, 2007.

Was this article helpful?

0 0
Blood Pressure Health

Blood Pressure Health

Your heart pumps blood throughout your body using a network of tubing called arteries and capillaries which return the blood back to your heart via your veins. Blood pressure is the force of the blood pushing against the walls of your arteries as your heart beats.Learn more...

Get My Free Ebook


Post a comment